Xbrane Biopharma Q3 2024: Deal or no deal - Redeye

Redeye makes slight adjustments to its forecasts following Xbrane's Q3 report, which indicated continued growth in end-customer sales. The primary near-term focus is on securing partnerships for XB003 and Xdivane by November to address the liquidity situation. This outcome is expected to be a determining factor for the share price trajectory moving forward.

Länk till analysen i sin helhet: https://www.redeye.se/research/1044730/xbrane-biopharma-q3-2024-deal-or-no-deal?utm_source=finwire&utm_medium=RSS